News about obesity

Novo said its next-generation obesity drug CagriSema led to an average 25% weight loss among women at 68 weeks in a new analysis following a late-stage trial, versus 3% with placebo. The result assumes all patients stayed on treatment without interruption, and Novo says further work is needed to confirm two post-study analyses. A separate analysis of about 1,900 women found weight loss of 26.7% in premenopausal, 24.8% in perimenopausal and 23.1% in postmenopausal women. The drug is expected to launch early next year, though investors have been lukewarm after earlier trial results fell short of expectations, and analysts forecast $11.84 billion in 2028 obesity sales per FactSet consensus.